Merck KGaA executives bet big on their own stock amid market slump
Top executives at Merck KGaA have made a bold move by buying more shares in the company. This comes as the pharmaceutical and technology firm faces a challenging year, with its stock price dropping by roughly 20% over the past 12 months. Despite the decline, insiders and major investors appear confident in its future. On 23 March 2026, Merck KGaA's share price fell by 4.24% on the Xetra exchange, closing at €102.80. The stock has seen significant volatility, trading between €82.52 and €132.30 over the last year. Currently, the company's market value stands at around €13.66 billion.
The recent insider purchases included CEO Belén Garijo López and Baroness Helene Röder von Diersburg. Their investments signal trust in the company's long-term prospects. BlackRock, the world's largest asset manager, also increased its stake, reinforcing this confidence. Merck KGaA operates across three key areas: Healthcare, Life Science, and Electronics. The Healthcare division provides stable income, while Life Science fuels growth with cutting-edge solutions. Meanwhile, the Electronics segment benefits from rising demand in AI and 5G technologies, helping diversify revenue streams. The company's strong regional presence in the DACH region and its defensive business model attract conservative investors. Analysts note that its balanced structure and innovation pipeline support resilience, even in uncertain markets.
The share purchases by executives and institutional investors suggest a belief in Merck KGaA's recovery and growth. With a diversified business model and exposure to high-growth sectors, the company remains positioned for long-term stability. The current share price, though down, reflects ongoing market fluctuations rather than fundamental weaknesses.
